To assess whether Gclc-OE T cells exhibit improved anti-tumor immunity in vivo, we adoptively transferred CD45.1+ Gclc-OE T cells and their counterparts in CD45.2+ B16F10-OVA tumor-bearing mice (Fig. 7g). Here, GCLC is linked to neoplasm.